Moderna· @moderna_tx · X·· 2026-06-09精选AI 评分52
AI 导读
Moderna与牛津大学宣布，其针对Lynch综合征的在研癌症疫苗mRNA-4194的1/2期研究已获英国MHRA授权。该试验是双方科学合作的一部分，旨在推进一种用于癌症预防的新型mRNA方法。
推荐理由
原文给出mRNA-4194在Lynch综合征中的临床阶段与授权机构，读者可据此了解mRNA癌症预防路径的早期进展。
正文
Today, along with the University of Oxford, we announced that a Phase 1/2 study of mRNA-4194, our investigational cancer vaccine for Lynch syndrome, has received Medicines and Healthcare products Regulatory Agency (MHRA) authorization in the UK. The trial is part of a scientific collaboration between Moderna and the University of Oxford to advance a novel mRNA approach to cancer prevention.
Read more: https://feeds.issuerdirect.com/news-release.html?newsid=8652502498876158&symbol=MRNA
来源：Moderna · x.com